Immune reset: CAR-T cells take on lupus and more

NCT ID NCT06548607

Recruiting now Disease control Sponsor: Nanjing Bioheng Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short chemotherapy-like prep. The main goal is to check safety and tolerability, while also looking for early signs that the therapy might control disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19 or CD19-BCMA CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new way to control severe autoimmune diseases by resetting the immune system.
What could go wrong: This is a very early, small trial (20 people) focused on safety. The treatment may not work, and there are risks like severe immune reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis autoimmune disease granulomatosis with polyangiitis myositis disease Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS AUTOIMMUNE DISEASES IDIOPATHIC INFLAMMATORY MYOPATHIES SJOGREN'S SYNDROME SLE (SYSTEMIC LUPUS) SYSTEMIC SCLEROSIS

Contacts and locations

Locations

The Third the People's Hospital of Bengbu
RECRUITING

Bengbu, Anhui, 233000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.